<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818998</url>
  </required_header>
  <id_info>
    <org_study_id>17613</org_study_id>
    <secondary_id>2014-004938-25</secondary_id>
    <nct_id>NCT02818998</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)</brief_title>
  <acronym>VIOLET</acronym>
  <official_title>An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of Three Different Treatment Regimens of 2 mg Aflibercept Administered by Intravitreal Injections to Subjects With Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different
      intravitreal (IVT) treatment regimens to subjects with DME pretreated with 2 mg aflibercept
      every 8 weeks after 5 initial monthly injections for approximately 1 year or more (according
      to the EU label for the first year of treatment)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2016</start_date>
  <completion_date type="Anticipated">November 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ETDRS BCVA (Early Treatment Diabetic Retinopathy Study - best corrected visual acuity) letter score for the study eye from baseline to week 52</measure>
    <time_frame>From baseline to week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ETDRS BCVA letter score for the study eye from baseline to week 100</measure>
    <time_frame>From baseline to week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CRT (central retinal thickness) in the study eye from baseline to week 52</measure>
    <time_frame>From baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CRT in the study eye from baseline to week 100</measure>
    <time_frame>From baseline to week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gained 10 or more letters from baseline to week 52</measure>
    <time_frame>From baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gained 10 or more letters from baseline to week 100</measure>
    <time_frame>From baseline to week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gained 15 or more letters from baseline to week 52</measure>
    <time_frame>From baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gained 15 or more letters from baseline to week 100</measure>
    <time_frame>From baseline to week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost 30 or more letters from baseline to week 52</measure>
    <time_frame>From baseline to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost 30 or more letters from baseline to week 100</measure>
    <time_frame>From baseline to week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to 100 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Aflibercept [Treatment A]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 mg aflibercept per injection once every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept [Treatment B]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 mg aflibercept per injection with interval equal to or more than 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept [Treatment C]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 mg aflibercept per injection on an as needed basis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <arm_group_label>Aflibercept [Treatment A]</arm_group_label>
    <arm_group_label>Aflibercept [Treatment B]</arm_group_label>
    <arm_group_label>Aflibercept [Treatment C]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject's history of aflibercept treatment meets all of the following:

               1. Treatment in the study eye was initiated with five monthly (-1 week /+2 weeks)
                  doses of 2 mg aflibercept and improvements of visual and anatomic outcomes were
                  observed and documented.

               2. Following the above initiation phase, the intervals between treatments were
                  between 6 weeks and 12 weeks (one exception will be allowed).

               3. The interval between the last two pre-study injections was ≥ 8 weeks, and visual
                  and anatomic outcomes have been stable over this interval.

               4. The subject received the last IVT (intravitreal) injection of aflibercept in the
                  study eye 8 weeks (±10 days) before the first planned treatment /randomization in
                  this study.

               5. Total prior treatment duration with aflibercept (i.e. from first aflibercept
                  treatment ever to enrollment into this study) was 1 year or longer.

          -  To be met at initiation of pre-study aflibercept treatment:

               -  Type-1 or -2 diabetes mellitus

               -  Diagnosis of DME (diabetic macular edema) secondary to diabetes mellitus
                  involving the center of the macula (defined as the area of the center subfield of
                  OCT) in the study eye

               -  Decrease in vision determined to be primarily the result of DME in the study eye

               -  BCVA in the study eye of ETDRS letter score 73 to 24 (corresponding to a Snellen
                  equivalent of approximately 20/40 to 20/320)

        Exclusion Criteria:

        At initiation of pre-study aflibercept treatment:

          -  Previous treatment with anti-angiogenic drugs in study eye (e.g. pegaptanib sodium,
             bevacizumab, ranibizumab or aflibercept) within the last 12 weeks before initiation of
             aflibercept pre-study treatment

        At all of the following time points:

        i) Initiation of pre-study aflibercept treatment ii) Screening for this study iii) Baseline
        for this study

          -  History of vitreoretinal surgery and/or including scleral buckling in the study eye

          -  Prior treatment of the study eye with

               -  Long acting steroids, either periocular or intraocular, in the preceding 120 days
                  or

               -  Iluvien intravitreal implant at any time

          -  Active proliferative diabetic retinopathy (PDR), current iris neovascularization,
             vitreous hemorrhage, or tractional retinal detachment in the study eye

          -  Cataract surgery within 90 days before aflibercept treatment in the study eye

          -  Pre-retinal fibrosis involving the macula of the study eye

          -  Structural damage to the center of the macula in the study eye that was likely to
             preclude improvement in BCVA following the resolution of macular edema including
             atrophy of the retinal pigment epithelium, subretinal fibrosis or scar, significant
             macular ischemia or organized hard exudates

          -  Concurrent disease in the study eye, other than DME, that could compromise VA (visual
             acuity), require medical or surgical intervention during the study period, or could
             confound interpretation of the results (including advanced glaucoma, retinal vascular
             occlusion, retinal detachment, macular hole, or choroidal neovascularization of any
             cause)

          -  Administration of systemic anti angiogenic agents within 180 days before aflibercept
             treatment

          -  Uncontrolled diabetes mellitus as defined by hemoglobin (Hb)A1c &gt; 12.0%

          -  Uncontrolled blood pressure (defined as systolic blood pressure &gt; 160 mmHg or
             diastolic blood pressure &gt; 95 mmHg while subject is sitting confirmed in two separate
             measurements)

        At all of the following time points:

        i) Screening for this study ii) Baseline for this study

          -  Any ocular or periocular infection in the preceding 4 weeks in either eye

          -  Filtration surgery for glaucoma in the past or likely to be needed in the future on
             the study eye

          -  Uncontrolled glaucoma (defined as intraocular pressure [IOP] &gt; 25 mmHg despite
             treatment with antiglaucoma medication) in the study eye

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug, might affect interpretation of the
             results of the study, or renders the subject at high risk for treatment complications

          -  Significant media opacities, including cataract, in the study eye that interferes with
             visual acuity, fundus photography or OCT (optical coherence tomography) imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3C 0G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <zip>40-594</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>91-134</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-285</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01-013</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiria</city>
        <zip>2410-197</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vila Franca de Xira</city>
        <zip>2600-178</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>85107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zilina</city>
        <zip>01207</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zvolen</city>
        <zip>960 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sant Cugat del Vallés</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <zip>1204</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunderland</city>
        <state>Tyne And Wear</state>
        <zip>SR2 9HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic macular edema</keyword>
  <keyword>DME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

